Dupilumab improves CRSwNP outcomes across type 2 inflammation profiles

Dupilumab improved outcomes among patients with severe chronic rhinosinusitis with nasal polyps across a range of type 2 inflammatory signatures, according to data presented at EAACI Hybrid Congress 2023 in Hamburg, Germany. Treatment also reduced local and systemic type 2 inflammation biomarkers and was well tolerated, Claus Bachert, MD, PhD, department of otorhinolaryngology, head and neck

Related Keywords

Germany ,Hamburg ,Sanofi Regeneron ,Byrichard Gawel ,Stallergenes Greer ,Claus Bachert ,Kristen Dowd ,European Forum For Research ,Astrazeneca ,Global Initiative For Asthma ,Novartis ,Airway Diseases ,University Hospital ,Sino Nasal Outcome Test ,Global Initiative ,European Position Paper ,Nasal Polyps ,European Forum ,